Q32 Bio Inc. 8-K

What Happened
Q32 Bio Inc. (QTTB) announced on May 26, 2026 that it entered into a securities purchase agreement with accredited PIPE investors to raise approximately $55 million in gross proceeds. Under the agreement the company will sell 6,725,000 shares of common stock at $8.00 per share and pre-funded warrants to purchase 150,000 shares (priced at $7.9999 each, with a $0.0001 exercise price). The company said the offering is expected to close on or about May 28, 2026, subject to customary closing conditions.

Key Details

• Offering size and price: 6,725,000 common shares at $8.00 each plus 150,000 pre-funded warrants at $7.9999 each; aggregate gross proceeds ≈ $55 million (before fees/expenses).
• Pre-funded warrant terms: exercisable anytime until exercised in full; holder cannot exercise if doing so would push beneficial ownership above 9.99% (ownership limit may be adjusted up to 19.99% upon 61 days’ notice).
• Registration rights: Q32 must file a registration statement covering resale of the shares and warrant shares within 50 days of closing and seek to have it declared effective.
• Placement agents: Morgan Stanley & Co. LLC (lead) and Oppenheimer & Co. Inc.

Why It Matters
This PIPE financing, if completed, would provide Q32 Bio with near-term capital to advance its clinical program for bempikibart and support general corporate purposes. For investors, the deal implies equity dilution (new shares and potential warrant exercises) but also improves the company’s cash position. The offering is not final until closing and the resale of the issued securities will be subject to a registration statement the company has agreed to file.